Claude R. Benedict
Director/Board Member at 2C Tech Corp.
Profile
Claude R.
Benedict is currently the Director at 2C Tech Corp., a Fellow Member at the Royal College of Physicians & Surgeons of Canada, and a Fellow Member at the American College of Cardiology Foundation.
In the past, he worked as the Senior Vice President & Head-Development at Archemix Corp., Principal at Aventis Pharmaceuticals, Inc., and SVP-Clinical Development & Regulatory Affairs at Viron Therapeutics, Inc.
Claude R. Benedict active positions
Companies | Position | Start |
---|---|---|
Royal College of Physicians & Surgeons of Canada
Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | Corporate Officer/Principal | - |
American College of Cardiology Foundation
American College of Cardiology Foundation Medical/Nursing ServicesHealth Services American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC. | Corporate Officer/Principal | - |
2C Tech Corp.
2C Tech Corp. Miscellaneous Commercial ServicesCommercial Services 2C Tech Corp. develops a medical device based on nanotechnology. It offers SeeQ device, which involves intraocularly delivered photoactive nanoparticles that converts light to electrical energy similar to a conventional solar cell but on a sub-cellular scale. The company is headquartered in Irvine, CA. | Director/Board Member | - |
Former positions of Claude R. Benedict
Companies | Position | End |
---|---|---|
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | - |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | General Counsel | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 6 |
---|---|
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Commercial Services |
2C Tech Corp.
2C Tech Corp. Miscellaneous Commercial ServicesCommercial Services 2C Tech Corp. develops a medical device based on nanotechnology. It offers SeeQ device, which involves intraocularly delivered photoactive nanoparticles that converts light to electrical energy similar to a conventional solar cell but on a sub-cellular scale. The company is headquartered in Irvine, CA. | Commercial Services |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
Royal College of Physicians & Surgeons of Canada
Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | Consumer Services |
American College of Cardiology Foundation
American College of Cardiology Foundation Medical/Nursing ServicesHealth Services American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC. | Health Services |
- Stock Market
- Insiders
- Claude R. Benedict